The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests
Open accessAbstract
Despite its history of success in cancer screening, Pap cytology has important limitations, particularly its high false-negative rate, which carries important public health implications. Since the mid-1990s, there has been substantial interest in the use of human papillomavirus (HPV) DNA testing in cervical cancer screening under the premise that the testing of cervical cells for the causative agent of cervical cancer could have acceptable screening performance, while being more reproducible in clinical practice than Pap cytology. There have been several studies assessing the utility of HPV testing compared with the Pap test as a screening tool. These studies varied widely in lesion-outcome definition and in methodology. No studies were based on cervical cancer incidence or mortality. No randomized controlled trials have yet been published; all of the studies were based on concomitant testing for HPV and cytology or additional tests. HPV testing has greater sensitivity (average, 27%) but somewhat lower specificity (average, 8%) than Pap cytology for detecting high-grade lesions. Screening of women aged 30 years or older tends to improve test specificity, but it also does so for cytology. The combination of cytology and HPV attained high-negative predictive values, which suggests that their joint use could allow screening intervals to be safely increased, thus lowering costs. Although evidence is yet to come from long-term studies and from randomized controlled trials with high-grade lesions and invasive cancer as outcomes, HPV testing is clearly one of the most promising new technologies and has the potential to improve cervical cancer-screening effectiveness in many settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Currently, there is interest in more widespread use of VIA in lowresource settings, 27 and there is a gradual adoption of HPV testing in many developed as well as developing countries.10”
From A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India (2005) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Studies, particularly in developed countries, suggest that HPV testing is more sensitive than cytology at identifying CIN 2=3 lesions but with lower specificity.10,[20][21][22][23][24][25]”
From A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India (2005) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
Wright, T. C. (2002) · JAMA · doi:10.1001/jama.287.16.2120 · Cited by 1,197
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
Stoler, M. H. (2001) · JAMA · doi:10.1001/jama.285.11.1500 · Cited by 1,087
Solomon, D., SCHIFFMAN, M. H., & Tarone, R. E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.293 · Cited by 958
Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia
Schlecht, N. F. (2001) · JAMA · doi:10.1001/jama.286.24.3106 · Cited by 590
Schiffman, M., Herrero, R., Hildesheim, A., Sherman, M. E., Bratti, M., Wacholder, S., Alfaro, M., Hutchinson, M., Morales, J., Greenberg, M. D., et al. (2000) · JAMA · doi:10.1001/jama.283.1.87 · Cited by 540
Wright, T. C. (2000) · JAMA · doi:10.1001/jama.283.1.81 · Cited by 468
Clavel, C., Masure, M., Bory, J. P., Putaud, I., Mangeonjean, C., Lorenzato, M., Nazeyrollas, P., Gabriel, R., Quéreux, C., & Birembaut, P. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1845 · Cited by 461
Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical Abnormalities
Kulasingam, S., Hughes, J. P., Kiviat, N. B., Mao, C., Weiss, N. S., Kuypers, J. M., & Koutsky, L. A. (2002) · JAMA · doi:10.1001/jama.288.14.1749 · Cited by 452
Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska, I., Rush, B. B., & SCHIFFMAN, M. H. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.46 · Cited by 429
Research works printed but not linked: 3
- Ratnam, 2000, Cancer Epidemiology Biomarkers & Prevention, 9, 945
- Womack, 2000, International journal of cancer. Journal international du cancer, 85, 206, 10.1002/(SICI)1097-0215(20000115)85:2%3C206::AID-IJC10%3E3.0.CO;2-Q · DOI
- Sellors, 2000, Canadian Medical Association Journal, 163, 513
Cited by
Sorted by citations
Worldwide burden of gynaecological cancer: The size of the problem
Sankaranarayanan, R., & Ferlay, J. (2005) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2005.10.007 · Cited by 726
Bulkmans, N. W. J., Berkhof, J. H., Rozendaal, L., van Kemenade, F. J., Boeke, A. J. P., Bulk, S., Voorhorst, F. J., Verheijen, R. H. M., van Groningen, K., Boon, M. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61450-0 · Cited by 647
Dillner, J., Rebolj, M., Birembaut, P., Petry, K.-U., Szarewski, A., Munk, C., de Sanjose, S., Naucler, P., Lloveras, B., Kjaer, S., et al. (2008) · BMJ · doi:10.1136/bmj.a1754 · Cited by 629
Clifford, G. M., Rana, R. K., Franceschi, S., Smith, J. S., Gough, G., & Pimenta, J. M. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0812 · Cited by 529
Arbyn, M., Sankaranarayanan, R., Muwonge, R., Keita, N., Dolo, A., Mbalawa, C. G., Nouhou, H., Sakandé, B., Wesley, R. S., Somanathan, T., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23489 · Cited by 318
Metadata
- Authors
- Franco, E. L.
- Affiliations
- McGill University (CA)
- Corresponding author
- Franco, E. L.
- ORCID
- Franco, E. L.
- Venue
- JNCI Monographs
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-06-01
- Volume
- 2003
- Issue
- 31
- Pages
- 89-96
- ISSN
- 1052-6773 (ISSN-L)
- 1745-6614
- OpenAlex
- W2135253681
- Cited by
- 146
- References
- 28
- Citations by year
- 2026: 2 · 2022: 4 · 2021: 2 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 2 · 2014: 6 · 2013: 6 · 2012: 10
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- JNCI Monographs (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- cervical cancer screening, HPV testing, Pap smear cytology, primary screening, false negative rate, high-grade cervical lesions, sensitivity and specificity, negative predictive value, screening interval extension, cost reduction
- MeSH terms
- Uterine Cervical Neoplasms, DNA, Viral, Ethics, Medical, Female, Humans, Mass Screening, Primary Prevention, Public Health, Sensitivity and Specificity, Tumor Virus Infections, Vaginal Smears, Observer Variation, Polymerase Chain Reaction, Ethics, Clinical, Papillomaviridae, Papillomavirus Infections, Ethics, Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
